factor

(redirected from Factor XIII deficiency)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.
Related to Factor XIII deficiency: Factor xii deficiency

Factor

A financial institution that buys a firm's accounts receivable and collects the accounts.

Factor

A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount. The factor then assumes the credit risk associated with the accounts receivable. This provides the firm immediate access to working capital, which is important, especially if the firm has a cash flow problem. The price of factoring is determined by the creditworthiness of the firm's customer, not of the firm itself. It is also known as accounts receivable financing.

factor

A firm that purchases accounts receivable from another firm at a discount. The purchasing firm then attempts to collect the receivables.

factor

To sell accounts receivable to another party at a discount from face value. Thus, a firm in need of cash to pay down short-term debt may decide to factor its accounts receivable to another firm.

factor

  1. a firm that purchases TRADE DEBTS from client firms. See FACTORING.
  2. a firm that buys in bulk and performs a WHOLESALING function.
  3. an input (for example raw material, labour, capital) which is used to produce a good or provide a service.

factor

  1. 1a FACTOR INPUT that is used in production (see NATURAL RESOURCES, LABOUR, CAPITAL).
  2. a business that buys in bulk and performs a WHOLESALING function.
  3. a business that buys trade debts from client firms (at some agreed price below the nominal value of the debts) and then arranges to recover them for itself. See FACTOR MARKET, FACTORING.
References in periodicals archive ?
Women with factor XIII deficiency have an increased incidence of fetal loss during pregnancy, although menorrhagia is not frequently seen.
The origin of the factor XIII deficiency in our 40-year-old patient remains unclear because his history was insignificant.
BioRx will apply a similar, personalized approach to the care of patients with factor XIII deficiency.
NovoSecure(TM) launched on March 26, 2015, and is open to people with hemophilia A, hemophilia A or B with inhibitors, congenital Factor VII deficiency, acquired hemophilia, Glanzmann's thrombasthenia, or congenital Factor XIII deficiency.
Individuals with congenital factor XIII deficiency have a high risk of bleeding into the brain and in soft tissues.
Label broadened to include the peri-operative management of surgical bleeding in adult and pediatric patients with congenital factor XIII deficiency